This company listing is no longer active
Immunovia Management
Management criteria checks 1/4
Key information
Jeff Borcherding
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | less than a year |
| Board average tenure | 5.8yrs |
Recent management updates
Recent updates
CEO
Jeff Borcherding (49 yo)
less than a year
Tenure
Mr. Jeff Borcherding served as Chief Executive Officer of US, Immunovia, Inc. at Immunovia AB (publ) since 2022 until April 2023 and since April 2023 serves as its Global Chief Executive Officer. He served...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Global Chief Executive Officer | less than a year | no data | no data | |
| President & Director | 1.3yrs | no data | 0% SEK 0 | |
| Chief Financial Officer | 1.1yrs | no data | no data | |
| Chief Operating Officer | less than a year | no data | no data | |
| Head of Clinical & Medical Affairs | less than a year | no data | no data |
0.3yrs
Average Tenure
54yo
Average Age
Experienced Management: IMMNOV BTA's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & Director | no data | no data | 0% SEK 0 | |
| Independent Chairman of the Board | 16.3yrs | SEK 580.00k | 3.78% SEK 7.3m | |
| Independent Director | 7.3yrs | SEK 280.00k | 0.10% SEK 197.4k | |
| Member of Scientific Advisory Board | 6.9yrs | no data | no data | |
| Independent Director | 1.1yrs | no data | no data | |
| Member of Scientific Advisory Board | 6.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 5.8yrs | no data | no data | |
| Independent Director | 1.1yrs | no data | no data | |
| Independent Director | 3yrs | SEK 288.00k | 0% SEK 0 | |
| Director | 2yrs | SEK 314.00k | 0% SEK 0 |
5.8yrs
Average Tenure
55yo
Average Age
Experienced Board: IMMNOV BTA's board of directors are considered experienced (5.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/05/07 07:32 |
| End of Day Share Price | 2023/05/04 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Immunovia AB (publ) is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Lars Hevreng | Danske Bank |
| Juan Pedro Rodríguez Serrate | Edison Investment Research |
| Alexandru Cogut | Kempen & Co. NV |